Podcast appearances and mentions of Michael Wong

This week on the Team Lally Real Estate Radio Show, we interview Michael Wong. Michael shares the heart and mission behind Laulima. He talks about how the program helps families in the gap—those who don't qualify for government support—and how donors, local businesses, and community partners keep the mission alive. Michael also speaks on their goals for 2025 and how Laulima continues supporting those in need even during the “off-season” of giving.We also have our Expert We Trust. Duke Kimhan of Hawaii Pacific Property Management shares how clarity from homeowners makes managing rentals much smoother. He talks about critical questions they ask on property walkthroughs, common maintenance issues, and how proactive property managers protect your investment.Who is Michael Wong?Michael Wong, our featured guest, was born in Kona and raised on Oʻahu. With a background as an educator, coach, and advertising professional, Michael brings a deep-rooted passion for serving Hawaiʻi's communities. Now, as the Business Development Specialist for the Laulima Giving Program, he channels his diverse experience into making a lasting impact across the islands—supporting keiki, kūpuna, and families through heartfelt initiatives.The Laulima Giving Program is a nonprofit dedicated to helping Hawaiʻi residents in need who may not qualify for traditional assistance. With programs like Back2School drives, Adopt a Family, and the Laulima Telethon, Laulima works year-round to bring hope and practical support to those facing hardship. Their mission is simple yet powerful: to uplift and empower local families by connecting them with the resources and compassion they deserve.To reach Michael Wong, you may contact him in the following ways:Phone: (808) 979-5283Email: laulima@koka.orgWebsite: LaulimaGivingProgram.org

This week on the Team Lally Real Estate Radio Show, we interview Michael Wong. Michael shares the heart and mission behind Laulima. He talks about how the program helps families in the gap—those who don't qualify for government support—and how donors, local businesses, and community partners keep the mission alive. Michael also speaks on their goals for 2025 and how Laulima continues supporting those in need even during the “off-season” of giving.We also have our Expert We Trust. Duke Kimhan of Hawaii Pacific Property Management shares how clarity from homeowners makes managing rentals much smoother. He talks about critical questions they ask on property walkthroughs, common maintenance issues, and how proactive property managers protect your investment.Who is Michael Wong?Michael Wong, our featured guest, was born in Kona and raised on Oʻahu. With a background as an educator, coach, and advertising professional, Michael brings a deep-rooted passion for serving Hawaiʻi's communities. Now, as the Business Development Specialist for the Laulima Giving Program, he channels his diverse experience into making a lasting impact across the islands—supporting keiki, kūpuna, and families through heartfelt initiatives.The Laulima Giving Program is a nonprofit dedicated to helping Hawaiʻi residents in need who may not qualify for traditional assistance. With programs like Back2School drives, Adopt a Family, and the Laulima Telethon, Laulima works year-round to bring hope and practical support to those facing hardship. Their mission is simple yet powerful: to uplift and empower local families by connecting them with the resources and compassion they deserve.To reach Michael Wong, you may contact him in the following ways:Phone: (808) 979-5283Email: laulima@koka.orgWebsite: LaulimaGivingProgram.org

“Just because your parents wanted the best for you in one way doesn't mean that you rebelling doesn't mean you still can't give back to them by living a good life.” Michael Wong is basically a cultural anthropologist for Asian America. A Seattle-based commentator, Michael's best known for Asian Verified on Instagram + TikTok, and also writes a monthly column for The Stranger, a Seattle newspaper. This is the first of many conversation with Filipino entrepreneurs GUEST-hosted by new FrieMMd of the Pod, past guest, and Filipina entrepreneur Lisa Angulo Reid.  LEARN MORE instagram.com/asianverified thestranger.com/collections/79782549/asian-verified GUEST HOST (Lisa Reid): https://dearflor.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textIn the latest episode of the award-winning podcast Inside Medical Malpractice, host Chris Rokosh continues to examine leaders in the world of patient safety with a riveting interview with Michael Wong, JD. Listen to the powerful story behind Michael's transformation from a successful defense attorney to a leading patient safety advocate. Driven by a promise made to the grieving mother of a young woman who died from opioid-induced respiratory depression while using a Patient Controlled Analgesia (PCA) pump in the hospital, Michael founded the Physician-Patient Alliance for Health and Safety. Tune in as Michael reveals the groundbreaking initiatives PPAHS is spearheading, including the development of checklists and standards for PCA's, DVT's, sepsis and mechanical ventilation care. He passionately discusses the critical need for practical ‘right now' solutions, marketing and cross-disciplinary collaboration to enhance patient safety.  His is clear about this: the need for a future where we work together to fix problems to make sure they don't happen again. Don't miss this inspiring episode that sheds light on Michael's relentless efforts to prevent medical errors and safeguard lives. And find out how you can help out at PPAHS.org.

(via ChatGPT) Humans and Belief in Magic https://chatgpt.com/share/67644975-22c0-8006-af08-9bab51dd1cad People prefer AI-generated poems to Shakespeare and Dickinson http://newscientist.com/article/2456291-people-prefer-ai-generated-poems-to-shakespeare-and-dickinson Michael Wong on Information, Function, and the Origin of Life https://pca.st/xwovbpsy o incrível trabalho do meu xará Renê de Paula: https://www.instagram.com/renedepaula_photography canal do radinho no whatsapp!https://whatsapp.com/channel/0029VaDRCiu9xVJl8belu51Z meu perfil no Threads: https://www.threads.net/@renedepaulajr meu perfil no BlueSky https://bsky.app/profile/renedepaula.bsky.social meu mastodon: ... Read more The post boas festas, raríssimes! muito obrigado! appeared first on radinho de pilha.

Living organisms seem exquisitely organized and complex, with features clearly adapted to serving certain functions needed to survive and procreate. Natural selection provides a compelling explanation for why that is so. But is there a bigger picture, a more general framework that explains the origin and evolution of functions and complexity in a world governed by uncaring laws of physics? I talk with planetary scientist and astrobiologist Michael Wong about how we can define what "functions" are and the role they play in the evolution of the universe.Support Mindscape on Patreon.Blog post with transcript: https://www.preposterousuniverse.com/podcast/2024/12/16/299-michael-wong-on-information-function-and-the-origin-of-life/Michael Wong received his Ph.D. in planetary science from Caltech. He is currently a Sagan Postdoctoral Fellow at the Carnegie Institution for Scienceʼs Earth & Planets Laboratory. He is in the process of co-authoring two books: A Missing Law: Evolution, Information, and the Inevitability of Cosmic Complexity with Robert M. Hazen, and a revised edition of Astrobiology: A Multidisciplinary Approach with Jonathan Lunine.Web siteCarnegie web pageStrange New Worlds podcastWong et al. (2023), "On the Roles of Function and Selection in Evolving Systems."Wong and Prabhu (2023), "Cells as the First Data Scientists."See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week on the Team Lally Real Estate Radio Show, we interview Michael Wong of the Laulima Giving Program. Michael discusses how his organization provides vital assistance to those in need and who don't qualify for government help. He shares how they adopt families, highlights a recent success story, and provides details on their upcoming events. We also learn how we can support their efforts and make a real difference in the lives of struggling families.We also have our Experts We Trust with their Tip of the Week. Duke Kimhan of Hawaii Pacific Property Management, explains why hiring a property manager is essential for investment property owners. He covers the importance of having an on-island representative and how a skilled property manager can make your life easier, protect your investment, and maximize its value. Dan Polimino from the Big Island shares a personal reflection on his recent trip with his son. He talks about the importance of being present and living in the moment, especially in our fast-paced lives. As a realtor, he also touches on managing the stress of helping clients with their real estate needs and why now is still a great time to buy a home.Who is Michael Wong?Michael was born in  Kona and raised on Oahu. He has had a diverse career as an educator, coach, and advertising professional before joining the Laulima Giving Program.The Laulima Giving Program is a community initiative by Keiki O Ka Aina Family Learning Centers. Through events like Back2School drives, Adopt a Family campaigns, and the Laulima Telethon with KHON2, they help support keiki, kupuna, and families in need across Hawaii. The essence of Laulima is to bring together many hands to lighten a heavy load. Their  mission depends on the kindness and generosity of companies and individuals in the community.To reach Michael, you may contact him in the following ways:Phone: (808) 221-5281Email: Michael.wong@KOKA.orgWebsite: https://laulimagivingprogram.org/

This week on the Team Lally Real Estate Radio Show, we interview Michael Wong of the Laulima Giving Program. Michael discusses how his organization provides vital assistance to those in need and who don't qualify for government help. He shares how they adopt families, highlights a recent success story, and provides details on their upcoming events. We also learn how we can support their efforts and make a real difference in the lives of struggling families.We also have our Experts We Trust with their Tip of the Week. Duke Kimhan of Hawaii Pacific Property Management, explains why hiring a property manager is essential for investment property owners. He covers the importance of having an on-island representative and how a skilled property manager can make your life easier, protect your investment, and maximize its value. Dan Polimino from the Big Island shares a personal reflection on his recent trip with his son. He talks about the importance of being present and living in the moment, especially in our fast-paced lives. As a realtor, he also touches on managing the stress of helping clients with their real estate needs and why now is still a great time to buy a home.Who is Michael Wong?Michael was born in  Kona and raised on Oahu. He has had a diverse career as an educator, coach, and advertising professional before joining the Laulima Giving Program.The Laulima Giving Program is a community initiative by Keiki O Ka Aina Family Learning Centers. Through events like Back2School drives, Adopt a Family campaigns, and the Laulima Telethon with KHON2, they help support keiki, kupuna, and families in need across Hawaii. The essence of Laulima is to bring together many hands to lighten a heavy load. Their  mission depends on the kindness and generosity of companies and individuals in the community.To reach Michael, you may contact him in the following ways:Phone: (808) 221-5281Email: Michael.wong@KOKA.orgWebsite: https://laulimagivingprogram.org/

Michael Wong is an author, speaker and meditation teacher who is internationally recognized for his work in the wellness community. His expertise brings together an integrative approach that combines evidence based breath-work, meditation insights and the advocacy of deep rest states. Michael is the Founder of Just Breathe, an education-based training organization and mindfulness app dedicated to helping people to breathe better, manage stress through meditation, and regulate the nervous systems. His podcast THE QUIET LIFE shares in-depth conversations with some of the world's leading psychologists, neuroscientists and thought leaders.This episode is proudly sponsored by:YETI, who's all about helping you embrace a life lived fully and actively, supported by gear that never lets you down. Head to https://www.yeti.com/ to start living every moment to its fullest!Seed®, a microbiome science company creating novel applications of bacteria like the DS-01® to support our gut and digestive health, designed to keep things moving. Head to Seed.com/EVERYBODY and use code 25EVERYBODY to get 25% off your first month of DS-01®..

Session 9 ‘Challenges and Solutions for Early Recognition and Treatment of Sepsis' from the 2024 WSC Spotlight. Featuring Patrick de Marie Katoto, Wiltrud Abels, Glenn Hernandez Poblete, Flavia Machado, Mark Ansermino, Michael Wong, and Eleanor Nwadinobi as your moderator.

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers.    TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I am an associate professor of medicine and the clinical director of the Melanoma Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I am delighted to have my colleague and friend Dr. Jason Luke on the podcast today to discuss key late-breaking abstracts and advances in immunotherapy that were presented at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the associate director of clinical research, and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center.   You will find our full disclosures in the transcript of this episode.  Jason, it's always a pleasure to hear your insights on the key trials in these spaces and to have you back as a guest on this podcast that highlights some of the work, especially advances, that were just presented. Dr. Jason Luke: Well, thanks very much for the invitation. I always love joining the podcast. Dr. Diwakar Davar: We'll start very quickly by talking about some advances and really interesting things that happened both in the context of melanoma but also in immunotherapy in general. And we'll start with what I think was certainly one highlight for me, which was LBA2, the late-breaking abstract on the NADINA trial. It was featured in the Plenary Session, and in this abstract, Dr. Christian Blank and colleagues reported on the results of this phase 3 trial of neoadjuvant ipi-nivo. This is the flipped dose of ipi1/nivo3 versus adjuvant nivolumab in PD-1 naive, macroscopic, resectable, high-risk stage 3 melanoma.  By way of background, neoadjuvant immunotherapy for those listening is an area of increasing interest for drug developers and development for both approved and novel agents. Neoadjuvant immunotherapy has been studied with multiple approved agents, including PD-1 monotherapy, PD-1 LAG-3, PD-1 CTLA-4, T-VEC, as well as investigational agents and multiple randomized and non-randomized studies. The benchmark pathologic response rates with these agents range from 17% PCR with PD-1 monotherapy, 45% to 55% PCR with PD-1 CTLA-4 combination therapy, and slightly higher 57% PCR with PD-1 LAG-3 has recently reported by Dr. Rodabe Amaria from MD Anderson. However, as we embark on phase 3 comparisons for various neoadjuvant compared to adjuvant immunotherapy trials and combinations, we're increasingly moving towards event-free survival as the primary endpoint for neoadjuvant versus adjuvant studies. And this was most recently studied in the context of SWOG S1801, a study that was led by Dr. Sapna Patel.  So, Jason, before we start on NADINA, can you briefly summarize the SWOG S1801 trial and the event-free survival statistic reported by Dr. Patel and her colleagues? Dr. Jason Luke: Well, absolutely. And these data were reported at ESMO about two years ago and then in the New England Journal last year. The S1801 study answered a very simple question: What would happen if you took three of the doses of standard adjuvant therapy with pembrolizumab and moved them prior to surgery? And on a high level, the study is as simple as that. And many of us were somewhat skeptical of this trial design because we thought that just moving the doses earlier may not actually have a major impact.  In the study, you alluded to the event-free survival statistic, and that alludes to what was considered an event. And so, without reading all of it, there were several different aspects that were included in terms of time, based on the date of randomization until the first of a series of events, such as disease progression, toxicity from treatment, if the patient was unable to go to surgery or had surgical complications, or if they had delay in starting the adjuvant therapy due to toxicity, and obviously, recurrence of melanoma or death from any cause. In that context, merely moving the 3 doses of pembrolizumab to the neoadjuvant setting saw an improvement in this two-year event free survival to 72% for the neoadjuvant therapy compared to 49% for the adjuvant therapy. That was quite an outstanding change. And again, noting the power of neoadjuvant treatment, really dictating the impact of anti PD-1, again, just with 3 doses moving from adjuvant into the neoadjuvant setting, and I think all of us were somewhat surprised to see that magnitude of a benefit. But it set up the current study very well, where we now look at combination therapy. Dr. Diwakar Davar: So let's move on to the phase 3 NADINA trial. Do you want to perhaps discuss the study design, particularly focusing on the EFS primary endpoint and maybe also touching on the different schedules? So, SWOG S1801 was a neoadjuvant study of 3 cycles of pembrolizumab and how did that compare and contrast to the neoadjuvant combination that was studied in NADINA? Dr. Jason Luke: Well, as you alluded to, NADINA investigated the regimen of nivolumab plus ipilimumab and compared that against adjuvant therapy with nivolumab alone. So, in the study, as you alluded, the dose and schedule of the two drugs used was nivolumab at 3 milligrams per kilogram, and ipilimumab with 1 milligram per kilogram. That was based on a series of signal finding and safety studies that had been previously done by the same group of authors identifying that as the optimal treatment regimen. And it's worth noting that's slightly different than the labeled indication that's generally used for those same drugs for metastatic melanoma, albeit that the NCCN also endorses this schedule. So, in the trial, 423 patients were randomized, 1:1 to receive either neoadjuvant therapy with those 2 doses of nivolumab plus ipilimumab as compared with standard adjuvant therapy with nivolumab following surgery.   Now, one interesting tweak was that there was an adaptive nature to the study, meaning that patients had a fiducial placed at the index lymph node, and after the neoadjuvant therapy in that arm, that lymph node was removed. And if the patient had a major pathological response, they did not go on to receive the adjuvant portion of the treatment. So it was adaptive because those patients who did very well to the neoadjuvant did not require the adjuvant portion. And in those patients who did not achieve a major pathological response, they could go on to have the adjuvant therapy. And that also included the BRAF therapy for those whose tumors were BRAF mutants.  It's also worth pointing out that the definition of event free survival was slightly different than in the S1801 study that was alluded to just a second ago. And here, EFS was defined from the date of randomization until progression due to melanoma or due to treatment. So that's slightly different than the definition in the S1801 trial. So, a somewhat complicated study, but I really applaud the authors because I think this study does mirror what we would likely be doing in actual clinical practice.  Dr. Diwakar Davar: So, just to briefly summarize the efficacy, and then to get your comments on this, the path response, the PCR rate was 47%. The major pathologic response rate, which is the proportion of patients with between 0% to 1/10% of residual viable tumors, was about 12%. And for a major pathologic response rate of 0% to 10% of 59%. And then the rest of the patients had either pathologic partial response, which was 10% to 50%, or pathologic non response or 50% or greater residual viable tumor, all assessed using central pathology grades. The one year RFS was 95% in the FDR patient population versus 76% in the pathologic partial response patient population, 57% in the pathologic non response patient population. So how do you view these results? Can you context the FDR rates and the EFS rates from NADINA relative to nivo-rela and also potentially SWOG 1801? Dr. Jason Luke: Well, I think these are very exciting results. I think that for those of us that have been following the field closely, they're actually not especially surprising because they mirror several studies that have come before them. When we put them in context with other studies, we see that these rates of major pathological response are consistent with what we've seen in phase 2 studies. They're relatively similar. Or I should say that the results from nivolumab and relatlimab, which was also pursued in a phase 2 study of somewhat similar design, are somewhat similar to this. So, combination immunotherapy does look to deliver a higher major pathological response than pembrolizumab alone, as was known in S1801. Which of course, the caveat being is these are cross control comparisons that we need to be careful about. So I think all of these are active regimens, and I think adding a second agent does appear to enhance the major pathologic response rates. When we look at the event free survival, we see something similar, which is that numerically it looks to be that combination immunotherapy delivers a higher event free survival rate. And that looks to be rather meaningful given the difference in the hazard ratios that were observed between these various studies. And here in the NADINA study, we see that 0.3 hazard ratio for EFS is just extremely impressive.  So the abstract then, from ourselves, out of these specific studies, what does this mean more broadly in the real world, where patients exist and the rest of the landscape for clinical trials? I think we can't take enough time to stop for a second and just think about what a revolution we've come forward in with immune checkpoint blockade and melanoma. When I started my career, now, more than 15 years ago, melanoma was the cancer that made cancer bad. And now here we say, in the highest risk of perioperative patients, we can deliver 2 doses of nivolumab and ipilimumab, and essentially half of the patients then don't need to go on, and more than half the patients don't need to go on to have a full surgery and don't need adjuvant therapy. And from what we could tell of a very, very low risk of every heavy recurrence of melanoma. Of course, there's the other half of patients where we still need to do better, but these are just fantastic results and I think highly meaningful for patients.   In the context of ongoing clinical trials, another abstract that was presented during the meeting was the update to the individualized neoantigen therapy, or V940 with pembrolizumab or against pembrolizumab alone. That's the KEYNOTE-942 study. In that study, they presented updated data at two and a half years for relapse free survival, noting a 75% rate without relapse. So those results are also highly intriguing. And these are in a similar population of very high risk patients. And so I think most of us believe that neoadjuvant therapy with this study in NADINA is now confirmed as the priority approach for patients who present with high-risk stage 3 disease. So that would be bulky disease picked up on a scan or palpable in a clinic. I think essentially all of us now believe patients should get preoperative immunotherapy. We can debate which approach to take, and it may vary by an individual patient's ability to tolerate toxicity, because, of course, multi agent immunotherapy does have increased toxicity relative to anti PD-1 alone. But we'll have to wait now for the full phase 3 results from the V940 individualized neoantigen therapy. And if those come forward, that will be an extremely attractive approach to think about for patients who did not achieve a major pathological response to neoadjuvant therapy, as well as of course to the other populations of patients with melanoma where we otherwise currently give adjuvant therapy stage 2B all the way through stage 4 resected. It's an amazing time to think about perioperative therapy in melanoma. Dr. Diwakar Davar: So this is clearly outstanding data, outstanding news. Congratulations to the investigators for really doing what is an investigative initiated trial conducted across multiple continents with a huge sample size. So this clearly appears to be, at this point in time at least, a de facto standard. But is this going to be FDA-approved, guideline-approved, or is it possible in your mind? Dr. Jason Luke: Well, that's an interesting question. This study was not designed with the intent to necessarily try to register this treatment regimen with the FDA. One would have to take a step back and say, with how powerful these data appear, it sort of seemed like it would be too bad if that doesn't happen. But all the same, I think the community and those of us who participate in guideline recommendations are fully supportive of this. So, I think we will see this move into compendium listings that support insurance approval, I think, very, very quickly. So, whether or not this actually becomes formally FDA approved or is in the guidelines, I think this should become the standard approach that is considered for patients, again presenting with high-risk stage 3 disease.  Dr. Diwakar Davar: Fantastic. So now we're going to go in and talk about a slightly different drug, but also from the melanoma context, and that is the safety and efficacy of RP1 with nivolumab in the context of patients with melanoma who are PD-1 failures. So, this is Abstract 9517. And in this abstract, our academic colleagues essentially talked about these data, and we'll start by describing what RP1 is. RP1 essentially is a HSV-1 based oncolytic immunotherapy. And RP1 expresses GM-CSF as well as a fusogenic protein, GALV-GP-R-. And in this abstract, Dr. Michael Wong from MD Anderson and colleagues are reporting the results of IGNYTE, which is a phase I trial of intratumoral RP1 co-administered with systemic nivolumab in patients with advanced metastatic treatment refractory cutaneous melanoma. And the data presented in this abstract represents data from a registration directed, abbreviated as RD, registration directed cohort of RP1 plus nivolumab in PD-1 refractory melanoma. So, let's start with the description of the cohort.  Dr. Jason Luke: Right. So, in this study, there were a total of 156 patients who were presented, and that included an initial safety and dose finding group of 16, as well as the RD cohort, as you noted, of 140 patients. And it's important to point out that this was a cohort that was selected for a very strict definition of progression on anti PD-1, or a combination immunotherapy as their immediately prior treatment. So, all of the patients in the cohort had exposure to anti PD-1, and 46% of them had anti PD-1 plus anti CTLA4, nivolumab and ipilimumab as their immediately prior therapy. This was also a group of relatively high-risk patients when one considers stage. So, within the stage 4 population, the entry here included 51% who had stage M1B, C, and D melanoma. And that is worth pointing out because this is an injectable therapy. So, trials like this in the past have tended to be biased towards earlier stage, unresectable or metastatic melanoma, meaning stage 3B, 3C, 3D and then stage 4m1a. Again, to emphasize the point here, these were pretreated patients who had a strict definition of anti PD-1 resistance, and over half of them, in fact, had high-risk visceral metastatic disease.  In that context, it's very interesting to observe that the overall response rate was described in the total population, as 31%, and that included 12% who achieved complete response. And so, again, to make sure it's clear, we're talking about a treatment where the oncolytic virus is injected into one or multiple sites of recurrent disease, and then the patients administer nivolumab as per standard. And so, I think these data are quite intriguing. Again, such a high- risk population and their maturity now, with a follow-up of over a year, I think, makes this look to be a very interesting treatment option.  Dr. Diwakar Davar: I guess on that topic of mature follow-up, it probably would be important for us to inform our audience that the top line data for the primary analysis was actually just released, I think, earlier today, and wherein the central confirmed objective response rate was 34% by modified RECIST and 33% by RECIST, clearly indicating that these responses, as you noted, very treatment refractory patient population, these responses were clearly very durable. So, you mentioned that there were responses seen in uninjected visceral lesions, responses seen in both PD-1 and PD-1 CTLA-4 refractory patients. Can you talk a little bit about the response rate in these high-risk subgroups, the uninjected visceral lesions, the patients who had both combination checkpoint and epidural refractory response rate by primary PD-1 resistance.  Dr. Jason Luke: Sure. You know, I think, again, to emphasize this point in the study, we saw that there were responses in the non-injected lesions, and I think it's really important to emphasize that. Some have referred to this as a putative abscopal like effect, similar to what is described in radiation. But it implies that local treatment with the oncolytic virus is triggering a systemic immune response. In the higher risk patient population, we'll note that whereas the overall response rate in PD-1 refractory patients was 34%, in the combination of PD-1 and CTLA-4 refractory patients, the response rate was 26%. So, [this is] still very good. And when we looked at that split by stage, as I alluded to before, in the population of patients that had, what you might call earlier unresectable diseases, so 3B through 4A, the response rate was 38%, and in the stage 4 M1b through M1d, it was 25%. So slightly lower, but still very good. And that would be as expected, because, of course, the patients with visceral metastatic disease have more advanced disease, but those response rates look quite good. Again, looking at the combination refractory population as well as the more high-risk disease. Dr. Diwakar Davar: So, clearly, these are very promising data and exciting times for multiple investigators in the field and the company, Replimune, as well. So, what are the next steps? I believe that a registration trial is planned, essentially, looking at this with the goal of trying to get this combination registered. Can you tell us a little bit about IGNYTE-3, the trial design, the control arm, and what you foresee this trial doing over the next couple of years?  Dr. Jason Luke: So, as this agent has been maturing, it's worth pointing out that the company that makes this molecule, called RP1, but I guess now we'll have to get used to this name vusolimogene oderparepvec as the actual scientific term, they have been having ongoing discussions with the FDA, and there is the potential that this agent could come forward on an accelerated path prior to the results being released from a phase 3 trial. That being said, the phase 3 confirmatory study, which is called the IGNYTE-3 study, is in the process of being launched now. And that's a study investigating this molecule in combination with nivolumab, as was alluded to earlier, and a randomized phase 3 design, where that combination is compared with a physician's choice, essentially a chemotherapy-based option.   In that study, it will be 400 patients with stage 3B through stage 4; patients will have progressed on anti PD-1, either as a combination or in sequence, and then come on the study to be randomized to either vusolimogene oderparepvec plus nivolumab versus that physician's choice. And the physician's choice includes chemotherapy agents, but also nivolumab plus relatlimab as another option, or an anti PD-1 monotherapy, if that's deemed to be a reasonable option by the treating investigator. And the primary endpoint of that study is overall survival. And unfortunately, in this highly refractory patient population, that's something that may not take long to identify with key secondary endpoints of progression free survival, as well as overall response rate. I'm quite enthusiastic about this study, given these data, which have now been centrally confirmed as you alluded to before. I think this is a very exciting area of investigation and really crossing my fingers that this may be perhaps the first locally administered therapy which does appear to have a systemic impact that can hold up in phase 3. Dr. Diwakar Davar: Very, very, very exciting results. And I guess it's worthwhile pointing out that this company also has got, I think, multiple studies planned with both RP1 and cutaneous squamous cell carcinoma in a solid organ transplant patient population where single agent activity has already been reported by Dr. Migden at prior meetings, as well as a novel trial of potentially RP2 metastatic uveal melanoma. So we'll now pivot to Abstract 6014. So, 6014 is a drug by a company known as Merus. Essentially, it's a very novel agent. Merus essentially is a company that is specialized in making bicyclics and tricyclics. And these are not bicycles or tricycles, but rather drugs that essentially are bispecific antibodies. And Merus essentially has come up with petosemtamab. I think we're going to have to figure out better names for all of these drugs at some point. But petosemtamab, or MCLA-158, essentially is a bicyclic, targeting both EGFR as well as LGR-5. So EGR-5, of course, is a known oncogenic driver in multiple tumor types, squamous, including non small cell lung cancer, cutaneous squamous cell carcinoma, but also head and neck squamous cell carcinoma. And LGR-5 essentially is leucine-rich repeat-containing G-protein coupled receptor 5, but it's a receptor in cancer stem cells and certainly highly expressed in head neck squam. And MCLA-158, or petosemtamab is a IgG one bispecific with ADCC-activity because of IgG1 backbone co-targeting EGFR and LGR5. Merus had earlier results that evaluated petosemtamab monotherapy. They defined the RP2D and second- and third-line head and neck blastoma patients with a respectable response rate of 37% investigator-assessed ORR with six months median DoR, and this was published by Ezra Cohen about a year or so ago.  In this abstract, Dr. Fayette and colleagues report on the results of the MCLA-158-CL01 trial, which is a trial of pembrolizumab plus petosemtamab in one front line head and neck squamous cell population. So maybe let's start with the description of the cohort. And it is a small trial, but we'll be able, I think, to dig into a little bit about why this might be exciting. Dr. Jason Luke: Yes. So, as alluded to, it's not the biggest trial as yet, but there were 26 patients with anti PD-1 treatment naive head and neck squamous cell carcinoma. And all the patients in the study did receive, as you alluded to, pembrolizumab plus petosemtamab. Based on the label for pembrolizumab, all the patients in this study were PDL-1 positive. So that's one point that it's worth pointing out to make sure that that's understood. This is the population of patients who would be expected to benefit from pembrolizumab in the first place. Now, in the abstract, they reported out only 10 response evaluable patients, but they updated that in the actual slides of presentation at the meeting. So among 24 patients that were alluded to, 67% were described as having had a response, although some of those were yet to be confirmed responses. And when it was evaluated by PDL-1 status, there didn't seem to be a clear enrichment of response in the PD-1 positive more than 20% group, as compared to the 1-19% group. That isn't especially surprising because that was a trend that one would see, presumably with pembrolizumab alone. But overall, I think these data are pretty exciting in terms of a preliminary study. Dr. Diwakar Davar: You know, you mentioned that the objective response rate was high, almost 60-something%. The prognosis of these patients is generally poor. The OS is typically thought of as between 6-15 months. And based on KEYNOTE-048, which was led by Dr. Burtness and colleagues, the standard of care in the setting is pembrolizumab +/- platinum based chemotherapy regimens. Allowing for the fact that we only have 10 patients here, how do you think these results stack up against KEYNOTE-048? And you made a very important point earlier, which was, by definition, pembro is on label only for the CPS. So PDL-1 score, at least in head and neck squamous cell carcinoma CPS and not TPS. But in the CPS 1% or greater patient population, where pembro is on label, how do these results stack up against the KEYNOTE-048 results. Dr. Jason Luke: Right. KEYNOTE-048 is considered the seminal study that dictates frontline treatment in head and neck cancer. And before we dive into this too far, we do want to acknowledge that here we're comparing 26 patients versus a phase 3 trial. So, we're not trying to get too far ahead of ourselves, but this is just a preliminary comparison. But in KEYNOTE-048, as you alluded to, two regimens were superior to chemotherapy. One was the pembrolizumab monotherapy, as well as pembrolizumab plus chemotherapy. So again, the study overall survival, of course, was much higher, the PDL-1 positive subgroup, which is what dictated the unlabeled use of this. But response to pembro monotherapy in that population of patients is still modest. We're talking about upwards of 20-30%. So, if you compare that to, again, preliminary evidence here from this trial of only 24 patients, that response rate of 60% seems extremely high. And so even if that were to come down somewhat in a larger data series of patients, that still looks to be quite promising as a treatment regimen, that might eventually even be chemotherapy sparing for this population of patients. I think this raises a lot of eyebrows that perhaps this dual targeting approach, EGFR and LDR-5, may bring something really important to the field that evolves it. Dr. Diwakar Davar: So, what are the next steps for petosemtamab? You mentioned that the activity was interesting. Are we going to see a larger trial? Any thoughts on where things are going to go?  Dr. Jason Luke: Well, based on the phase 2 data of petosemtamab alone, even without pembrolizumab, the molecule had already been given fast track designation by FDA, which means allowing for greater communication between the drug sponsor in the FDA and designing a seminal study design. One would assume that this trial will be rapidly expanded quite greatly, perhaps to 100 or 200 patients, to try to flush out what the real response rate is in a more meaningful number of patients. But I think these data will probably also trigger the design and probably near-term evaluation or expedited acceleration of a phase III clinical trial design that would potentially validate this against the current standard of care. So, I'm pretty excited. I think we'll see a lot more about this agent in the relatively near future. Dr. Diwakar Davar: So, finally, we'll pivot to the last abstract that we're going to talk about, which is Abstract 2504. It's a relatively interesting target, CCR8 monoclonal antibody. But this is the efficacy and safety of LM-108, and LM-108 is an anti CCR8 monoclonal antibody that is being developed by LaNova Medicine. And the results that are described, actually a pool set of results of combinations of LM-108 with anti PD-1, two separate anti PD-1, in patients with gastric cancer, mostly done ex-U.S., which is interesting because of this patient population, and it's a pool result of several, 3 phase 1 and 2 studies.  LM-108 is an Fc-optimized anti CCR8 monoclonal antibody that selectively depletes tumor infiltrating Tregs. The abstract reported a pooled analysis of three phase 1, 2 trials with 3 different NCT numbers that all evaluated the efficacy of LM-108 and anti PD-1 in patients with gastric cancer. So, let's start with the description of the cohort. Maybe, Jason, you can tell us a little bit about before you start, as you describe the cohort, sort of what we know, editorially speaking, about the difficulty with which Tregs depletion has been tried and obviously failed up until now in the tumor microenvironment. Dr. Jason Luke: Right. I think that's a really interesting comment. And so, for decades, in fact, targeting regulatory T-cell to alleviate immune exclusion in the tumor microenvironment has been of interest in immuno-oncology. And in preclinical mouse models, it seems quite clear that such an approach can deliver therapeutic efficacy. However, by contrast, in human clinical trials, various different Treg depleting strategies have been attempted, and there's really little to no evidence that depleting Tregs from human tumors actually can deliver therapeutic responses. And by that we're referring to CD-25 antibodies. The drug ipilimumab, the CTLA-4 antibody, was punitively described as a Tregs depleter preclinically, but that doesn't seem to be the case in patients. And so, in that background, this is quite an eye raiser that an anti CCR8 antibody could be driving this effect. Now, before we talk about the results of this trial, I will point out, however, that given the Fc-optimization, it's entirely possible that the Tregs are being depleted by this mechanism, but that more could also be going on. Because Fc gamma RII binding by this antibody that could be nonspecific also has the potential to trigger immune responses in the tumor microenvironment, probably mediated by myeloid cells. So I think more to come on this. If this turns out to be the first meaningful Tregs depletor that leads to therapeutic efficacy, that would be very interesting. But it's also possible this drug could have multiple mechanisms.  So, having said all of that, in the clinical trial, which was a pooled analysis, like you mentioned, of LM-108 in combination with anti PD-1 of a couple different flavors, there were 48 patients treated either with LM-108, with pembrolizumab, or with toripalimab, which is another anti PD-1 antibody. On the drug combination was, generally speaking, pretty well tolerated, noting grade 3 treatment related adverse events in the range of 38%, which is somewhat expected given combination immunotherapy. We talked about nivolumab and ipilimumab before, which, of course, gives even higher rates of immune-related adverse events, with the most common toxicities being anemia, lipase elevations, rash, ALC decrease; albeit, quite manageable. Dr. Diwakar Davar: So, what about the objective response rate? Can you contextualize the efficacy? And as you do that, maybe we'll think about what you'd expect in the context of, say, gastric cancer, especially in patients who've never really had a prior checkpoint inhibitor before. What do you think about the ORR? What do you think about the relative efficacy of this combination? Dr. Jason Luke: Well, so, in the study, they described overall response rate in the 36 patients as 36% and described immediate progression for survival of about 6.5 months. And so that was among patients who were treatment naive. And in second-line patients, they actually described an even higher response rate, although it was only 11 patients, but they're at 64%. And so, I think those data look to be somewhat interesting. When I was actually scrutinizing the actual data presented, it was of some interest to note that the quality of responses seemed to be about as good on the lower dose of LM-108, so 3 milligrams per kilogram as compared to 10 milligrams per kilogram. I think there's definitely more to learn here to try to optimize the dose and to fully understand what the overall efficacy of this treatment combination would be.  I would emphasize that in this disease, I think novel treatment strategies are certainly warranted. While anti PD-1 with chemotherapy has moved the needle in terms of standard of care treatment, it's really only a minor subset of patients who derive durable long-term benefit like we normally associate with immune checkpoint blockade. I think these are preliminary data. They're very intriguing.   You alluded to earlier that this population of patients was an Asian data set, and it is well known that the efficacy of chemotherapy and immunotherapy does appear to be somewhat enhanced in Asian populations, and that goes to distributions of metastasis and tumor microenvironment effects, etc. Very difficult to try to tease any of that out in this abstract, other than to look at these data and suggest that this is pretty interesting, both from a novel therapeutic approach, we talked about the Tregs consideration, but also straight up on the efficacy because I think if these data could hold up in a larger number of patients, and particularly in a western population of patients, I think it would be very intriguing. Dr. Diwakar Davar: Certainly, ASCO 2024 had a lot of interesting data, including data from targeted agents, the LAURA trial, ADCs. But just focusing on the immune therapy subset, we certainly saw a lot of great advances in patients who were treated with neoadjuvant as well as relapse refractory disease in the context of RP1 and then a couple of newer agents such as this petosemtamab as well as LM-108. And of course, we cannot forget to highlight the extended DMFS data from the pembro vaccine study from KEYNOTE-942.  Jason, as always, thank you for taking a little bit of time out of your extremely busy schedule to come and give us insights as to how these agents are impacting the landscape. We really value your input and so thank you very much.  Dr. Jason Luke: Thank you for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for your time today. You will find the links to all the abstracts that we discussed in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. So, thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:       Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy       Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

(Previously published exclusively on the website, this episode is now available in the podcast feed). Wong or Wrong is over. Bonus content isn't as we take a look at In The Line Of Duty 4 with Michael Wong alongside the daredevil and asskicking duo Cynthia Khan and Donnie Yen and First Option from 1996 which […]

(Previously published exclusively on the website, this episode is now available in the podcast feed). Wong or Wrong is over. Bonus content isn’t as we take a look at In The Line Of Duty 4 with Michael Wong alongside the daredevil and asskicking duo Cynthia Khan and Donnie Yen and First Option from 1996 which […]

In this episode I talk with Michael Wong and Collin Creach from Outbuild. TOPICS COVERED: Why Outbuild choose to focus on construction scheduling, How to get buy-in on a construction schedule, What differentiates Outbuild from the competition, the importance of investing in the front end on planning/scheduling, building construction projects digitally before building them physically, how to build a simple solution to a complex problem in a powerful way, and the future / what's to come in our industry/Outbuild. SHOUT OUTS/MENTIONS: Elon Musk, Albert Einstein, Adam Hoots, Construction Brothers, Get Construction Talking, Primavera, Procore --- Send in a voice message: https://podcasters.spotify.com/pod/show/sethyoufree/message

The sci-fi film Dune: Part Two is out in theaters now. The movie takes place on the harsh desert planet, Arrakis, where water is scarce and giant, killer sandworms lurk just beneath the surface. But what do planetary scientists and biologists think about the science of these worms, Arrakis and our other favorite sci-fi planets? Today on the show, Regina G. Barber talks to biologist (and Star Trek consultant!) Mohamed Noor and planetary scientist Michael Wong about Dune, habitable planets and how to make fantasy seem more realistic. Want more of the science behind your favorite fictional worlds? Email us at shortwave@npr.org. Listen to Short Wave on Spotify, Apple Podcasts and Google Podcasts. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Elwood and Stephen look at the Michelle Yeoh classic Royal Warriors which would also become the second film in the long running Line of Duty series. Here she plays a Hong Kong Police officer who has to team up with Hiroyuki Sanada's Japanese detective and Michael Wong's air marshal to stop a terrorist group out for revenge!! Buy us a coffee and support the show⁠⁠⁠⁠⁠⁠⁠ Check out our sponsor: ⁠⁠⁠⁠⁠⁠⁠Yes Please Vintage

The Museum's Creativity Series continues with a conversation on the importance of connection, collaboration, and community. Through a grant from LEGO, called the LEGO Playful Learning Museum Network, institutions across the country were tasked with creating a community of practice that focused on playful learning Joining us today are three representatives from LEGO's community of practice who connected over a shared interest in Tinkering Inventive Playsets, Nick Villagra from the Connecticut Science Center, Michael Wong from the Exploratorium, and Brendan Takenaga from Boston Children's Museum. Tune in to learn about how a community of practice operates, where creativity exists in our work, the power of inspiration, half-baked ideas, open communication between peers, and more! Learn more about this partnership on the Exploratorium Blog. Or connect with our guests by emailing Nick at nvillagra@ctsciencecenter.org, Michael at mwong@exploratorium.edu, or Brendan at Takenaga@bostonchildrensmuseum.org.

We welcome Michael Wong, paranormal investigator to the show this week. Michael has taken his love for history and the paranormal and created PN Paranormal. On his channel he investigates haunted locations and explores the history behind these hauntings. Michael shares with us his creepy encounters in an abandoned asylum, hospitals an old haunted prison and an experience with a booty touching spirit you won't wanna miss. Catch him on his YouTube channel. https://youtube.com/@p.nparanormal?si=WuASkVuNYGbI9igx --- Support this podcast: https://podcasters.spotify.com/pod/show/raphael-gonzalez2/support

In this episode, we return to the world of Digital Asynchronous Consulting Systems (DACS) and ponder how digital changes might be implemented in general practice during a time of chaos for the NHS, as it has its 75th Anniversary. We get a fake 5-year old's opinion on DACS systems, before hearing from Michael Wong and Sandeep Singh from Engage Health Systems, who have developed a system called Engage Consult, a digital asynchronous consultation system (DACS), which is already in use in England but is new to Scotland. We covered the following ground in the conversation: Why is Engage Consult a configurable digital asynchronous consultation system (DACS) that can be tailored to meet the specific needs of healthcare practices? How is collaboration with other services facilitated? How can implementation vary based on organizational structure, such as Primary Care Networks (PCNs) in England or a more practice-level focus in Scotland? What are the automation features for intelligent routing and assignment of patient requests? What is the integration with Vision and EMIS PC? How much will the system cost? How are implementation and support approached? Video demonstrating the Engage Consult system from the SNUG Members Day 2023 (log in needed) Engage Health website Technology Enabled Care explainer on DACS systems The birth of the NHS Summertime Blues – the Who

Welcome!

Continuing our Pride Month 2023 special with queer entrepreneur and LGBTQ advocate Kayla Wong. Born and raised in Hong Kong, many would have come across Kayla as the daughter of actor Michael Wong and supermodel Janet Ma. But after living the majority of her formative years in the limelight, Kayla made a name for herself as an outspoken LGBTQ advocate in Hong Kong. She joins us to talk about how paparazzi played a part in her coming out experience, being out and proud in the social media age, and what we can do to advance LGBTQ+ acceptance in Asia given the cultural nuances. Follow Kayla on Instagram: https://instagram.com/kaylaiw ------------------------------------------------------- Stay Connected with Proudly Asian: Website - ⁠https://proudly-asian.com⁠ Instagram - ⁠https://instagram.com/proudly.asian⁠ Youtube - ⁠https://www.youtube.com/@proudlyasianpodcast Send us a voice message - ⁠https://anchor.fm/proudlyasian/message⁠ Support us - https://ko-fi.com/proudlyasian Email us - ⁠proudlyasianpodcast@gmail.com

Dr. Michael Wong is a Carnegie Postdoctoral Fellow at the Carnegie Institution for Science's Earth & Planets Laboratory working with Robert M. Hazen, Shaunna M. Morrison, Peter Gao, and others. His primary scientific interests are planetary atmospheres, habitability, biosignatures, and the emergence of life. He is also co-authoring a revised edition of the textbook Astrobiology: A Multidisciplinary Approach with Professor Jonathan Lunine. Dr. Wong's other passions include photography, writing, public speaking, graphic design, and playing a variety of team sports. He hosts a podcast called Strange New Worlds, which examines science, technology, and culture through the lens of Star Trek. Please check out these links from the episode: Strange New Worlds Website Twitter Instagram Boldly Go! Welcome to Dice in Mind, a weekly/biweekly podcast in which we explore the meaning of life through the lens of RPGs!  In each episode, we will consider everyday stuff like science, religion, philosophy, and economics…through the lens of a specific roleplaying game and its dice mechanic. If you like what you hear, consider buying us a cup of coffee or becoming a patron.  You can also join the conversation by following us on Facebook. Music by Kevin McCloud courtesy of Creative Commons by Attribution 3.0 license (https://www.youtube.com/c/kmmusic/featured).

Urologists Tan Yung Khan and Michael Wong talk about these large kidney stones.

Season 4: Episode 1--The UP Notable Book Club presents author Phyllis Michael Wong speaking about her book We Kept Our Towns Going: The Gossard Girls of Michigan's Upper Peninsula. The Crystal Falls Community District Library in partnership with the U.P. Publishers & Authors Association (UPPAA) presents author events with winners of the UP Notable Book List.  For more information please visit the links below www.UPPAA.org   www.UPNotable.com  https://msupress.org/9781611864205/we-kept-our-towns-going/  Phyllis Michael Wong, a native of the San Francisco Bay area, would follow her father's sage advice of “listen, talk little, listen” in her roles as a historian; educator, including as a writing instructor and director of online learning; and 30-year member of the university-level academic world, including as First Lady at Northern Michigan University (2004-12) and San Francisco State University (2012-19). Among her favorite First Lady accomplishments is co-founding a One Book, One Community county-wide reading program at NMU. Michigan's Upper Peninsula is known for its natural beauty and severe winters, as well as the mines and forests where men labored to feed industrial factories elsewhere in the nineteenth and twentieth centuries. But there were factories in the Upper Peninsula, too, and women who worked in them. Phyllis Michael Wong tells the stories of the Gossard Girls, women who sewed corsets and bras at factories in Ishpeming and Gwinn from the early twentieth century to the 1970s. As the Upper Peninsula's mines became increasingly exhausted and its stands of timber further depleted, the Gossard Girls' income sustained both their families and the local economy. During this time the workers showed their political and economic strength, including a successful four-month strike in the 1940s that capped an eight-year struggle to unionize. Drawing on dozens of interviews with the surviving workers and their families, this book highlights the daily challenges and joys of these mostly first- and second-generation immigrant women. It also illuminates the way the Gossard Girls navigated shifting ideas of what single and married women could and should do as workers and citizens. From cutting cloth and distributing materials to getting paid and having fun, Wong gives us a rare ground-level view of piecework in a clothing factory from the women on the sewing room floor.

     This week the second starring role for one of Hong Kong's most bad ass stars and a film made by a son of a Bond.      When Hong Kong detective Michelle Yip, air security guard Michael Wong, and hardboiled Tokyo detective Yamamoto team up to stop a crime boss's daring in flight escape. Little do the expect that it would set them, and all the care about, in the sights of a pair of revenge focused blood brothers. Michelle Yeoh steps out of the supporting role and into butt kicking lead glory- Royal Warriors.     Asher lost his hearing 20 years ago when his brother was murdered by Ivan. News of Ivan's early release from prison sets Asher on a path of revenge against the man he has dreamed of killing for most of his life. There's just two small complications, the ridiculous script and the fact that Ivan is Asher's father. Sean Brosnan's attempt at Dixie fried revenge- My Father Die.     All that and Dave feels some feelings. Kevin starts to horde physical media, and Tyler marvels at the Thrasher pictures still glues to his wall. Join us, won't you?   Episode 298- Futurity Ne'er Expires

In this episode, we're joined by Michael Wong, the founder of Mizko Media and The Designership.With a platform of over 100K on YouTube, Michael shares with us how he built a large and engaged following on YouTube and social media and emphasises the importance of learning 'soft skills' as a natural introvert and balancing trial and error with striving for perfection. Michael also shares his insights on the perfect business model from his extensive experience in the tech industry and how he started 'The Designership' to help businesses grow.Show Notes Links:https://www.thedesignership.com/https://www.mizko.net/https://linkedin.com/in/mizkohttps://youtube.com/mizkohttps://instagram.com/mizko

Friends, colleagues, and Crime Family--what do you get when a serial rapist isn't put away with hard time? You get two senseless and infuriating murders (at least--maybe more) of Swedish women, who each had their whole lives left to live. Bailey will bring you the stories of Engla Högland and Pernilla Hellegren, who both deserved better, but who were stolen from their lives by the same disturbed man.Beth is in the palate cleanser seat, and is telling you about Doctor Michael Wong. This man is not only a life-changing doctor and patient advocate, he was attacked and nearly killed in the Melbourne, Australia hospital where he was a neurosurgeon. Hospital security is only one of the meaningful causes he now champions, as he invents new ways to save lives, both in the operating theater and amongst his healthcare colleagues. So if you came here today looking for stories of true crime that will both make you grateful for your own safety and also celebrate the survivors amongst us, you've come to the right place. This is what we do at the True Crime BnB. Welcome aboard--we're glad you're here. Now, have a seat, grab a glass, and let's get started. Meow. . . . . .If you enjoy our show, please share our episodes on social media--that's the greatest way to help us find new listeners.Another way is to rate and review on Apple Podcasts or GoodPods, or give us a 5-star rating on whatever platform you prefer!https://linktr.ee/TrueCrimeBnB?utm_source=linktree_profile_share<sid=9e8aa538-d3ee-4823-b2e1-cb1625692e7aYou can find us on Instagram, Twitter, or Facebook @TrueCrimeBnBYou can send us an email at TrueCrimeBnBPod@gmail.comAnd lastly, we would love and appreciate any amount of your support at Patreon, here:https://patreon.com/TrueCrimeBnB?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=creatorshare_creator

In this episode, you'll learn how social impact and environmental sustainability can work together. We chat with Michael Wong, Environmental Sustainability Manager with Ferguson, and explore everything about GHG emissions as well as how to start and scale an environment and sustainability program in your business.   00:53 - What should we understand about GHG emissions? 3:20 - Is there standard reporting for GHG emissions? 4:23 - What is net-zero, and how is it connected to ESG? 6:35 - How can social impact professionals impact environmental and sustainability efforts in their organization? 9:41 - Successful examples of environmental and sustainability programs   11:07 - How to start a sustainability program at a smaller company?   12:06 - As a social impact pro, how would you start building a sustainability program?   13:36 - How to scale your sustainability programs

This week on the Team Lally Radio Show we interview Michael Wong of the Laulima Giving Program. We talk about how the program serves the community and how the community can give back in return.We also have your favorite experts providing this week's tips on property management, mortgage loans, home inspection and home insurance!Who is Michael Wong?Michael Wong was born in Kona and was raised here on Oahu. He is an only child born to two wonderful parents. He attended Hawaiian Mission Academy, K-12. He enjoys golf, the ocean and playing music. He was an educator, a Coach, an athletic Director, Advertising Sales and now for a local Christian native Hawaiian nonprofit organization. He is currently the Business Development Manager for the Laulima Giving Program.Laulima Giving Program is one of the many programs managed by the Keiki O Ka Aina Family Learning Centers. Its mission is assisting underprivileged families year round. The program brings companies and individuals together to help families in Hawaii. The Laulima Giving Program depends solely upon the kind and generous donations from the local business communities.To reach Michael, you may contact him in the following ways:Phone: (808) 843-2502Email: Michael.wong@KOKA.orgWebsite: www.LaulimaGivingProgram.org

This week on the Team Lally Radio Show we interview Michael Wong of the Laulima Giving Program. We talk about how the program serves the community and how the community can give back in return.We also have your favorite experts providing this week's tips on property management, mortgage loans, home inspection and home insurance!Who is Michael Wong?Michael Wong was born in Kona and was raised here on Oahu. He is an only child born to two wonderful parents. He attended Hawaiian Mission Academy, K-12. He enjoys golf, the ocean and playing music. He was an educator, a Coach, an athletic Director, Advertising Sales and now for a local Christian native Hawaiian nonprofit organization. He is currently the Business Development Manager for the Laulima Giving Program.Laulima Giving Program is one of the many programs managed by the Keiki O Ka Aina Family Learning Centers. Its mission is assisting underprivileged families year round. The program brings companies and individuals together to help families in Hawaii. The Laulima Giving Program depends solely upon the kind and generous donations from the local business communities.To reach Michael, you may contact him in the following ways:Phone: (808) 843-2502Email: Michael.wong@KOKA.orgWebsite: www.LaulimaGivingProgram.org

Time for exciting news! This is my first week at Fortune as a Sales Account Director. Sharing with you why I choose this incredible opportunity.   Thank you, Lindsey Kintner who will be my manager for the opportunity. Thank you to Lisa Cline and Alison Fried for sharing your vision and allowing me to be one of the earliest team members growing the Fortune Connect business. Shout out to Michael Wong for sharing with me how incredible of a manager she is, and big thanks to the LinkedIn product for showing me who is connected to whom always a big help during the interview process. Here are some of the reasons why I choose Fortune and why the Fortune Connect product. I got to experience meeting Arvind Krishna who the CEO and Chairman of IBM, who shared his insights into the incredible opportunities ahead of us, and met one of my favorite authors Keith Ferrazzi who wrote the playbook on how to add value to your network. His book Never Eat Alone made a big difference in my life. Fortune has had 93 years of history of cultivating and grooming the most impactful executives in the world and has brought together many extraordinary leaders. To be able to continue to grow that and build the legacy is truly a privilege. There are so many takeaways from completing the Building Stakeholder Capitalism course. I've also learned a lot from the Purpose-Driven Leadership learning sprints. This role combines my love for mentoring, executive coaching, and community-building. I'm grateful for the opportunity to make a difference and cultivate the next generation of C-suite executives within the Fortune 500, the top most prominent organizations in the world. https://youtu.be/ii4bKZCG3Jg #FortuneConnect #fortune500companies  

Today, I had the incredible privilege of interviewing Michael Wong, who is the Senior Vice President of Global Sales at Digital Turbine. He is responsible for creating the global vision, driving revenue growth, and establishing the go-to-market strategies in 3 regions. These are my top ten takeaways from our conversation1. Active Listening2. Value 3. Having a winning mentality4. Growth Mindset and being receptive to candid feedback5. Understanding the competitive landscape6. Challenger Sales7. Sending Pre-reads8. Being a strategic and tactical leader9. Out-prepping your competition 10. Operational RigorWe discuss interviewing best practices, being super curious, and putting in what's missing. We reflected on the amazing lessons we learned at LinkedIn and how it's stayed with us as we implement those lessons in our careers. Thank you, Mike, for your mentorship. Check out this episode if you are interviewing. This is a great listen for anyone in sales. If you want to ask Mike any questions, feel free to reach out to him on LinkedIn. https://www.linkedin.com/in/michael-wong-91932/

Today, I had the incredible privilege of interviewing Michael Wong, who is the Senior Vice President of Global Sales at Digital Turbine. He is responsible for creating the global vision, driving revenue growth, and establishing the go-to-market strategies in 3 regions. These are my top ten takeaways from our conversation1. Active Listening2. Value 3. Having a winning mentality4. Growth Mindset and being receptive to candid feedback5. Understanding the competitive landscape6. Challenger Sales7. Sending Pre-reads8. Being a strategic and tactical leader9. Out-prepping your competition 10. Operational RigorWe discuss interviewing best practices, being super curious, and putting in what's missing. We reflected on the amazing lessons we learned at LinkedIn and how it's stayed with us as we implement those lessons in our careers. Thank you, Mike, for your mentorship. Check out this episode if you are interviewing. This is a great listen for anyone in sales. If you want to ask Mike any questions, feel free to reach out to him on LinkedIn. https://www.linkedin.com/in/michael-wong-91932/

Today, Michael Wong talks us through how the breathing techniques you learn in mediation and yoga can benefit your running when you're clocking up the miles. Hosted on Acast. See acast.com/privacy for more information.

In today's clip, Michael Wong, a leading voice in the global movement for modern mindfulness, answers the simple yet essential question: how can we all meditate?To listen to the full episode, please visit:Well Far on SpotifyWell Far on Apple Podcasts Hosted on Acast. See acast.com/privacy for more information.

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. In the Research Round Up series, ASCO experts and members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today's episode, our guests will discuss new research in lung cancer, lymphoma, and childhood cancer that was presented at the 2022 ASCO Annual Meeting, held June 3-7 in Chicago, Illinois. First, Dr. Charu Aggarwal will discuss 3 studies looking at treatment options for people with non-small cell lung cancer. Dr. Aggarwal is the Leslye Heisler Associate Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania's Perelman School of Medicine in Philadelphia, Pennsylvania. She is also the Cancer.Net Associate Editor for Lung Cancer. You can view Dr. Aggarwal's disclosures at Cancer.Net. Dr. Aggarwal: Hello and welcome to this Cancer.Net podcast. I'm bringing you updates from the Annual Meeting of the American Society of Clinical Oncology, held in Chicago in 2022. I'm Dr. Charu Aggarwal. I'm the Leslye Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania's Abramson Cancer Center. I will be discussing updates on 3 studies today that offer insights and new advances in the management of patients with non-small cell lung cancer. I don't have any direct relationship with any of these companies or studies, and you can view a list of my disclosures on the Cancer.Net website. First off, I would like to talk a little bit about advances in the management of patients with EGFR exon 20 mutations. We know that a lot of advances have been made in the management of patients with non-small cell lung cancer, and much of that has been attributed to the fact that we are now able to deliver targeted therapy for a subset of patients. EGFR mutations form one such subset where we have a lot of oral drugs that are available, and we can offer these that improve survival, and patients can avoid chemotherapy, immunotherapy, and other IV infusional therapies. Within the subset of EGFR mutations lies this unique subset of EGFR exon 20 insertion mutations, which have been historically harder to target with currently available EGFR inhibitors. And over the last 5 years, we have seen tremendous growth of opportunities, targets, and new drugs for this subset of patients. The mutations in this subset forms about 2% to 5% of all non-small cell lung cancers. But now we have 2 FDA-approved drugs in this space, one being intravenously administered, amivantamab, and another that is orally available, mobocertinib. We covered this in a podcast as well as a blog, so please check those out on our Cancer.Net website. But building upon that progress, there is now another drug that was reported at ASCO. This drug is called CLN-081. And we saw preliminary activity in a phase 1 and 2 study of this molecule or this drug in patients with EGFR exon 20 insertion mutations. It's an orally available drug. The top line data is that it is safe, it is effective, it was tested in different doses. It was tested at less than 65 milligrams, 100 milligrams, and 150 milligrams, again, as I mentioned, administered orally, and we saw responses and patients that had previously received other therapies and may have progressed on other therapies. And what we found was that this drug also tends to have activity against brain metastases, which I think is this huge unmet need in the management of such patients. So I think more to come, but again, I think offers us an insight into what may be in the future, an attractive drug for our patients with EGFR exon 20 insertion mutations. So stay tuned, more on that in the future. Shifting gears, I would like to now talk about one of the common mutations. So we talked about EGFR exon 20, which is about only 2% to 5%, but the largest subset of mutations in non-small cell lung cancer really revolves around KRAS mutations, and these form about 30% to 35% of all mutations in non-squamous, non-small cell lung cancer. And amongst this group there is another subset which is KRAS G12C non-small cell lung cancer, that forms about 13% of all lung cancers. We have 1 approved drug already in this space by the name of sotorasib that is FDA approved for the management of patients with this particular mutation after having received 1 prior therapy, be it chemo-immunotherapy or immunotherapy. At this year's ASCO meeting, we heard data from a study called KRYSTAL-1, which looked at the activity and safety of another molecule called adagrasib, which is an orally available drug targeting KRAS G12C, again, in a similar population of patients with advanced and metastatic non-small cell lung cancer harboring a mutation. We found that this drug is again effective, the overall response rate was about 43%, the majority of the patients had stabilization of disease, about 80%, and many patients were able to remain on treatment with stabilization of disease. We found that this drug does have side effects and adverse events and most commonly of this were diarrhea, nausea, vomiting, and fatigue. Many patients did require dose reductions, but the activity of the drug remained despite dose reductions. Now, what would be the advantage of this drug against the currently available sotorasib? In another smaller study reported at ASCO, there seemed to be activity in the brain, including intracranial penetration with the use of this molecule, adagrasib, which has not been demonstrated before with other KRAS G12C inhibitors, so I think that makes it a potentially attractive option. Again, I will say that the report of this intracranial activity was in a very small subgroup of patients, so I think needs to be further corroborated in a larger study. Shifting gears again and talking about our last study, so I would like to highlight what do we do if, in case, patients don't have a targetable mutation. I want to highlight that we do have a lot of available options, and we are continuing to improve upon available options. The way we treat such patients is by using immunotherapy, either alone or in combination with chemotherapy. But what do we do after this treatment stops working? Researchers from the Southwestern Oncology Group, or SWOG, launched a massive national effort called Lung-MAP, which is basically a clinical trial that evaluates several different strategies all at once, either for patients with targetable mutations or for patients without a targetable alteration. And they reported results from a study that evaluated the combination of pembrolizumab with ramucirumab in patients that may have progressed after frontline immunotherapy. Now, pembrolizumab is immunotherapy, so the concept was, can we continue immunotherapy beyond progression and perhaps get some synergistic activity by using ramucirumab, which is a drug that prevents blood vessels from forming in the tumor itself. It's an anti-angiogenic agent, meaning that it is a targeted molecule that prevents blood vessel formation and promotes tumor death. What they found was that patients that received pembrolizumab and ramucirumab were more likely to live longer, so overall survival was longer for patients with this combination compared to a physician investigator discretion choice, such as chemotherapy in combination with ramucirumab or other chemotherapies that are otherwise used in the second line setting. And interestingly, we did not find a significant improvement in shrinkage with this combination of pembrolizumab and ramucirumab or a significant reduction in the time of progression-- or, sorry, prolongation of the time of progression of disease. But the overall survival findings are interesting, and I think that's why we are including them in this podcast because that's one of the approaches that is leading to an improvement in survival and improvement in outcomes. I will point out that this is a phase 2 study. These results would need to be validated in a large prospective phase 3 trial so that we can account for certain confounding factors that may have led to these results. Having said that, I think there's a tremendous excitement, there's tremendous excitement in this field. I gave you examples of, or highlighted, 3 studies: one in patients with EGFR exon 20 insertion mutations, another in KRAS G12C mutations, and the third in patients who may have already received either immunotherapy or chemoimmunotherapy. We will continue to update our Cancer.Net website with updates as they come through, new advances, new studies, so thanks for following, thanks for listening, and more to come. Stay tuned. Thank you. ASCO: Thank you, Dr. Aggarwal. Next, Dr. Christopher Flowers will discuss new research in treating people with different subtypes of lymphoma, including mantle cell lymphoma and diffuse large B-cell lymphoma. Dr. Flowers is the Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center and was appointed Division Head ad interim of Cancer Medicine in August 2020. He is also the 2022 Cancer.Net Associate Editor for Lymphoma.   You can view Dr. Flowers' disclosures at Cancer.Net. Dr. Flowers: Hello and welcome to this podcast that is a review of late breaking abstracts from the ASCO Meeting and recent updates in lymphoma. I'm Dr. Christopher Flowers, professor and chair of the Department of Lymphoma and Myeloma and Interim Division Head for Cancer Medicine at The University of Texas MD Anderson. And it's my great pleasure to discuss with you some of these late breaking abstracts. I do have some disclosures that are related to the content that I will present from this year's ASCO Meeting and recent studies in lymphomas. Those are available at Cancer.Net. Those relate to my role as a consultant for the development of clinical trials in lymphomas and research funding that MD Anderson has received from companies related to my role in clinical trials in lymphoma and clinical trials across cancers. So, the ASCO Meeting had a host of new information that was presented. Some of that information centers around key clinical trials. One that was a pivotal clinical trial, the SHINE clinical trial, looked at patients with mantle cell lymphoma, a rarer lymphoma subtype, that looked at the combination of bendamustine and rituximab, a standard chemoimmunotherapy combination, compared to that same chemoimmunotherapy combination, bendamustine, rituximab, plus the Bruton's tyrosine kinase inhibitor ibrutinib. Ibrutinib, as some of you may know, is a kind of therapy that is typically used in the relapse setting for patients with mantle cell lymphoma when they have their disease come back. And the SHINE clinical trial was looking at adding it to frontline therapy. What this randomized, controlled trial in the phase 3 setting found was that patients who received the combination of bendamustine, rituximab, plus ibrutinib had improvement in their progression-free survival, meaning that the time that it took for their disease to come back or them to have deaths related to the lymphoma was longer for patients who received this combination. About 2.3 years longer than the group that received bendamustine, rituximab, plus placebo. And in total, that led to a median progression-free survival of 6.7 years. That study has now been published in the New England Journal of Medicine and was led by my colleague Dr. Michael Wong from MD Anderson. Dr. Wong also led another study that was presented at the ASCO Meeting looking at CAR T-cell therapy for patients with mantle cell lymphoma. That study has now been published in the Journal of Clinical Oncology, and it looks at brexucabtagene autoleucel, a kind of CAR T-cell therapy, where that-- the CAR T-cell therapy was successfully manufactured for 71 of the 74 patients in the trial. 68 of those patients received an infusion and the median progression-free survival, so the average amount of time that it took for patients to have progression of their disease, was about 25 months. And so a marked benefit for those patients who were receiving CAR T-cell therapy when their mantle cell lymphoma came back. There also were major breaking abstracts at the ASCO Meeting in the area of diffuse large B-cell lymphoma. As many of you may know, diffuse large B-cell lymphoma is the most common type of lymphoma that occurs in the United States. And there was a breaking trial that was presented in December at the American Society of Hematology Meeting describing polatuzumab, a CD79b antibody drug conjugate, as a new drug in the substitution of frontline therapy for patients with diffuse large B-cell lymphoma in combinations with rituximab, cyclophosphamide, adriamycin, and prednisone, or the pola-R-CHP arm, that compared favorably to rituximab and CHOP chemotherapy, which has been the standard of care for patients with diffuse large B-cell lymphoma. And that trial showed an improvement in progression-free survival. At this year's ASCO Meeting, Franck Morschhauser presented results from looking at subsets of that patient population. Those patients who had BCL2 by immunohistochemistry that was positive or MYC expression by immunohistochemistry that was positive, or both of those, what we call double-expressor lymphomas, those who have poorer risk than standard groups. And those double-expressor lymphomas, treated with pola-R-CHP, had improvement in progression-free survival compared to R-CHOP with a hazard ratio of 0.64 in that group. We also saw in a multitude of analysis that that supported the benefit of pola-R-CHP in patients with both BCL2-positive and MYC-positive diffuse large B-cell lymphoma. Another area that has been very hot in diffuse large B-cell lymphoma clinical trials is the role of bispecific antibodies. Bispecific antibodies are antibodies that bind both to CD20, a marker on the diffuse large B-cell or the lymphoma cells, and to the marker CD3, which is a marker on T-cells which brings the normal T-cells of the immune system in close proximity to the lymphoma cells and then leads to immune-directed killing of lymphoma cells. The agent glofitamab is an agent that was presented by Michael Dickinson at this year's ASCO Meeting in an abstract. And in this study, 107 patients who received more than 1 dose of steady treatment went on to have complete responses in about 35% of patients. And this showed that glofitamab induced durable complete responses and had a very favorable safety profile in patients with relapsed and refractory diffuse large B-cell lymphoma. And in this trial, they compared that also for patients who had prior exposure to CAR T-cells and showed that responses were also good in those patients. Another set of studies has also looked at bispecific antibodies and a whole host of other areas with multitude of other agents. Another study that was presented at this year's ASCO Meeting explored the use of bispecific antibodies in the frontline setting in combination with the R-CHOP regimen that I just discussed. In that study, Lorenzo Falchi presented results of the subcutaneous bispecific antibody epcoritamab in combination with R-CHOP. This was a relatively small study of 33 patients that showed that the combination of epcoritamab plus R-CHOP was something that was safe and tolerable. There were no new treatment emergent adverse events that led to discontinuation of epcoritamab in the study. And there are some adverse events that are of special interest that we see with the bispecific antibodies, and those include the kind of immune-mediated adverse events that we can also see with CAR T-cells, like cytokine release syndrome, or CRS, or neurologic toxicities that we can see there that are also called ICANS. What we've seen in this trial, that about 42% of patients had some form of cytokine release syndrome, but that most severe form of cytokine release syndrome, those that were greater than grade 3 in severity, was only in 3% of patients. And likewise, the neurologic toxicities, or ICANS, that were grade 2 was in only 3% of patients. Relatively few patients completed all therapy by the time that this was presented. Only 10 patients had completed 6 cycles of therapy, but that showed an overall response rate that was quite high in that patient population. There were a whole host of other trials that were presented at this year's ASCO Meeting, and those portend improved kinds of outcomes on the horizon for patients with lymphomas across the spectrum. And I think it's an exciting time moving forward for clinical trials in lymphoma and hopefully, to see new therapies that emerge for the management of this disease. One of those new therapies that happened outside of the ASCO Meeting was the recent FDA approval of CAR T-cell therapy in the relapse setting for follicular lymphoma. And this was based on the ELARA clinical trial. And I think the future is quite bright for therapies and for patients with lymphomas broadly. ASCO: Thank you, Dr. Flowers. Finally, Dr. Daniel Mulrooney will discuss new research in childhood cancers, including a study comparing treatment options for Ewing sarcoma, and several studies on neuroblastoma. Dr. Mulrooney is an Associate Member in the Division of Cancer Survivorship at St. Jude Children's Research Hospital. He is also the Cancer.Net Associate Editor for Pediatric Cancers. You can view Dr. Mulrooney's disclosures at Cancer.Net. Dr. Mulrooney: My name is Dr. Dan Mulrooney from St. Jude Children's Research Hospital. I'm the Deputy Director of the After Completion of Therapy Clinic at St. Jude and primary care for survivors of pediatric solid tumors. The annual ASCO Meeting is typically quite busy and full of research presentations sharing knowledge and advances in cancer treatment and care. Today, I'd like to highlight some of the exciting presentations in pediatric cancer. Please note, I do not have any relationships to disclose related to any of these studies. At this year's meeting, one of the highlights was a European study in patients with relapsed or refractory Ewing sarcoma. Ewing sarcoma is a rare bone cancer that typically occurs in adolescents or young adults. While challenging to treat, it is difficult to cure in patients who have relapsed, and studies are needed to improve the care of these patients. Investigators from 13 European countries and Australia and New Zealand studied the most common relapsed therapies, which include irinotecan and temozolomide, gemcitabine and docetaxel, topotecan and cyclophosphamide, or high-dose ifosfamide. The study enrolled 451 patients between 2014 and 2021 and randomly assigned them to one of these four treatments. Based on response rates, the first 2 arms were dropped and the study was largely a comparison between topotecan cyclophosphamide and high-dose ifosfamide. The main outcome was event-free survival. Event-free survival is a common way in a clinical trial to see how well a treatment works. It measures the time from treatment that the patient remains free of complications, such as return or progression of the cancer. But investigators also looked at overall survival, toxicity, and quality of life. The 6-month event-free survival was better for high-dose ifosfamide at 47% compared to 37% for topotecan cyclophosphamide. The median overall survival was also better for high-dose ifosfamide compared to topotecan cyclophosphamide. The results were best for children younger than 14 years old versus those 14 or greater. Toxicities included fever and neutropenia, nausea, vomiting, and diarrhea. Patients receiving high-dose ifosfamide had more neurologic and kidney toxicities, which might be expected since ifosfamide is known to affect these organ systems, while only descriptive measurements of quality of life appeared higher for those children treated with high-dose ifosfamide compared to topotecan and cyclophosphamide. The strength of this trial is its large size, particularly for a rare cancer, and the fact that it randomized patients to the most commonly used treatment regimens for relapsed Ewing sarcoma. Importantly, data did not previously exist comparing these different treatments. While the results of this study are promising, clearly more needs to be done, and there was a lot of discussion at the ASCO Meeting about how to further improve survival in these patients. This study provides some information for doctors and patients, but importantly, provides data to advance future trials, which will concentrate on incorporating new targeted drugs with high-dose ifosfamide. This study is ongoing and is adding additional arms to continue to improve the outcomes for patients with relapsed or refractory Ewing sarcoma. In addition to this study in Ewing sarcoma, several studies investigating neuroblastoma were presented. Neuroblastoma is the most common extracranial solid tumor in children and for children with high-risk disease requires intensive and prolonged treatment, including chemotherapy, surgery, radiation therapy, and stem cell transplantation. Treatment for these patients has improved since the introduction of immunotherapy, particularly an antibody directed at a particular antigen named GD2 on the neuroblastoma cells. One study showed improvement in outcomes using this antibody for children with relapsed or refractory neuroblastoma, and another study demonstrated feasibility of using this antibody earlier in treatment, which was not previously known to be safe and tolerable. In what is called the BEACON study, investigators tested whether the antibody, called dinutuximab, would be effective when combined with chemotherapy for relapsed or refractory neuroblastoma. They enrolled 65 patients from 2019 to 2021 and randomized these patients to either chemotherapy alone or chemotherapy plus dinutuximab. The median age of these children was 4 years. The overall response rate, which means either a complete or partial response, was 18% for the chemotherapy-only arm but improved to nearly 35% for those treated with chemotherapy and dinutuximab. The progression-free survival was 27% for chemotherapy only and improved to 57% for those treated with chemotherapy and the antibody. There was no change in overall survival, though investigators think this may have been due to some patients who had progressive disease and crossed over to the antibody arm of the study. This presentation was followed by a study from the Children's Oncology Group, which investigated the feasibility of adding antibody treatment earlier in the treatment regimen for neuroblastoma. Prior studies had used antibody later in treatment when the tumor burden is thought to be lower. The endpoint of this study was tolerability measured by toxic deaths or unacceptable toxicities, such as adverse reactions to the medication. For example, sustained low blood pressure requiring a ventilator or breathing machine, or severe neuropathy. 42 high-risk neuroblastoma patients were enrolled from 8 different children's hospitals between 2019 and 2021. 41 of the 42 were able to complete the induction chemotherapy plus the antibody. There were no toxic deaths or unacceptable toxicities. Importantly, 85% were able to complete the next phase of treatment, called the consolidation phase, and 79% were able to complete the following phase after consolidation, called post-consolidation. One-year event-free survival was 83%, and 1-year overall survival was 95%. Now, it's important to know these are still early results, and the trial recently closed, and some of the patients have only completed therapy within the last year. Both of these studies add to the knowledge of chemoimmunotherapy for children with high-risk neuroblastoma. These studies provide a foundation for larger randomized trials that will further advance the care of these children. And finally, another study looked at race, ethnic, and socioeconomic disparities among children treated for high-risk neuroblastoma on Children's Oncology Group studies. There were no differences in event-free survival, but there were differences in overall survival based on ethnicity. The 5-year survival was lowest for Hispanic patients at 47%, 50% for non-Hispanic other ethnicities, which included Asian, Native American, Native Hawaiian, or Pacific Islanders, and 62% for non-Hispanic Black and non-Hispanic White children. Importantly, these investigators also studied household and neighborhood poverty. Overall, survival was lower for children living in poverty, though some of these differences went away when accounting for other factors, such as stage of disease or high-risk features. This study is important because it highlights the increasing need to collect data on clinical trials that may contribute to inequities in outcomes. While most studies collect data on the race and ethnicity of participants, other factors known as social determinants of health, such as income, neighborhood, education, access to health care, and insurance coverage, may also contribute to outcomes in pediatric cancer patients. Overall, the studies highlighted here and presented at this year's ASCO Annual Meeting focused on difficult-to-treat cancers, such as relapse or refractory disease, and they have laid the groundwork for future investigations to continue to improve survival rates for all children diagnosed with a malignancy through improved therapies and by addressing potential social barriers. Thank you for listening to this brief summary of the new research in pediatric oncology presented at the 2022 ASCO Annual Meeting. ASCO: Thank you, Dr. Mulrooney. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

A true pioneer Camille Vidal, also known as Mindfull Cami, is on a mission to inspire the world to bring mindfulness into the glass showing that Tasty Doesn't have to be Boozy. For her its all about celebrating Epic Nights & Early Mornings for a hangover-free life. Mindfully Cami is a globally recognised bartender and drinks expert turned mindfulness, yoga and Meditation teacher.   Ashley sits down with Cami for a Bizzimumzi chat discussing all the feelings around new news of carrying twins, bringing the boys into the world the best way she could with her partner, Michael Wong, and maintain her thriving business, La Maison.    Learn more about Camille Vidal's buisness La Maison here: https://www.lamaisonwellness.com/   We love hearing from you! Get in touch with any topic suggestions, questions and feedback at:  info.bizzimumzi@gmail.com   Follow Bizzimumzi on Istagram:  https://tinyurl.com/BizzimumziInstagram    

When bodybuilder Richard Bagdonas was diagnosed with cancer at the age of forty-five, he set out to design a new fitness regimen to help him fight that battle. One that would keep his mind and body strong enough to win. After beating stage IV cancer—and then COVID pneumonia—Richard started sharing his workout story and building a dedicated community of FitFAB warriors. 01:31: Just a few years ago, my family and I went to Mexico.  02:56: I sat down in her office, and I said I have cancer. 05:00: I wrote a letter email to Dr. Michael Wong at MD Anderson. 07:14: Were there any side effects from the immunotherapy? 09:15: Did your doctors think you were crazy? 11:19: I started writing the book during the very first month of cancer treatment. 13:25: I was going back and forth to Houston quite often. 15:14: Cancer that was in my body was completely gone.  17:12: When they ran a CT scan, they found a benign tumor behind her left eyeball the size of an eyeball.  19:51: In 2019 I was cured of cancer.  22:22: I had 30% lung capacity at the time. 25:08: When I was at the hospital, I was vegetarian.  26:11: What is one thing you wish you had known at the beginning of your cancer journey? 26:53: If you could only do one thing to improve health care in the U.S., what would it be and why?  28:14: Thriver Rapid Fire Questions.  29:38: Aside from Cancer U, what's one resource you would recommend for cancer patients and caregivers?  Resources Fit For Any BattleRichard on LinkedInRichard on TwitterEmail Richard

“Know yourself, know your enemy, know your ability and know your surroundings.” – Master WongMy guest this episode is Michael Wong, known to the world as Master Wong.  He is the first martial artist to successfully use YouTube as a teaching platform with a reach of almost 3 Million followers.  His high energy and dynamic teaching style along with engaging content has inspired and educated millions of viewers.  He is truly an internet trailblazer.This episode is all about Master Wong's story and his drive to overcome bullying, gangs, and how martial arts has transformed his life.  My key take away is Know Yourself to Know Your Enemy.  We have to develop an awareness and understand our abilities, be able to read our opponents and gage the threats in our surroundings.  This awareness is vital to choosing the correct tactics and strategies in dangerous situations.  We discuss training strategies, teaching methods, and martial arts mindset and philosophy.  Master Wong's stories of overcoming adversity are inspirational, and he lives and breathes what he teaches.

To listen to the full episode, please visit:Well Far on SpotifyWell Far on Apple PodcastsToday, I've got brilliant advice from Michael Wong to share with you. Michael is a leading voice in the global movement for modern mindfulness, a community activist, yoga and meditation teacher, speaker and author. In season one of Well Far I asked him “how can runners enjoy yoga when tight hamstrings and eagerness to run keeps them off the mat?” Hosted on Acast. See acast.com/privacy for more information.

Will and Matt are here to discuss "one of the most universally acclaimed motion pictures in the history of Hong Kong cinema..." (Not their words.)  Topics Include:-Hong Kong Knife Fights!-Fosters and Pills!-Flirting in 1998? Change Her Light Bulb!-plus much more!DISCLAIMER: Language and Spoilers!BEAST COPSdir. Gordon Chan, Dante Lamstarring: Anthony Chau-Sang Wong, Michael Wong, Stephanie Che

This week's episode is all about cultivating mental fortitude to thrive on your marathon journey. Amy begins by chatting to the founder of Just Breathe and Boys of Yoga, Michael Wong, about the benefits of yoga and how connecting to your breath can help on your running journey. Amy then heads off on a run with Aimee Fuller, a Team GB Olympian snowboarder who will soon be adding the London Marathon to her list of accomplishments. They talk about Aimee's ascent from childhood gymnast to Team GB snowboarder and the mental strength required to hit those kickers.How to find out more about today's experts:Michael Wong, Website: www.justbreatheproject.com Instagram: @michaeljameswongAimee Fuller, Instagram: @aimee_fuller See acast.com/privacy for privacy and opt-out information.

Achieving balance requires discipline, practice, and a realistic framework. Over time, with consistent effort, you will find yourself getting better and better at it until it is second nature. The definition of balance, however, is very personal and different for every individual. It takes time and attention to understand what your version of balance is that makes you feel energetic in the various aspects of your life. Rob explains exactly how he evolved into his current state of balance and now keeps it going with ease. Michael Wong and Alex Comfortes founded Peeka VR to get kids excited about reading again. They use visual technology to immerse children in stories with the goal of igniting their passion for reading and learning. But sitting between two slow moving industries, publishing and education, they want to know how to move fast and disrupt. Justin Kershaw had spoken with Rob in 2020 when he was introduced by Outstanding Foods CEO and Founder, Bill “Billy G” Glaser. Rob couldn't quite see the vision of Sow Strong Food back then. But that didn't stop Justin. He went out and hustled to bring his brand to life, and Rob is incredibly impressed. He wasn't coming on the show looking for a deal with Dyrdek Machine, but you never know what can happen on Build With Rob.  Learn more about this episode.

Today on The Fastest Growing Companies podcast, we're talking to the Founder and CEO of DayBlink, Michael Wong. Check out the video version on YouTube. Host: Chris Ronzio Learn more about Trainual, the world's top Business Playbook™ software.

Adrienne Lally · Family Assistance in Hawaii with Michael WongThis week on the Team Lally Real Estate Radio Show, we interview Michael Wong of the Keiki O Ka ‘ Āina Family Learning Centers. We'll be talking about how the Laulima Giving Program brings companies and individuals together to help families in Hawai`i.We also have your favorite experts providing this week's tips on property management, mortgage loans, home inspection and home insurance!Who is Michael Wong?Michael Wong is the Program Development Coordinator for the Laulima Giving Program with the Keiki O Ka Aina Family Learning Centers. He was born and raised in Hawaii, has 3 children and 5 grandchildren. He enjoys anything in the ocean, golfing and supporting UH sports. He Graduated with a BS in Education, has been a teacher, Coach and Athletic Director for 20 years, and a Media Sales Consultant since 1994.To reach Michael you may contact him in the following ways:Phone: 808-843-2502Email: laulima@koka.orgWebsite: http://laulimagivingprogram.org/To get the latest Covid-19 information and its impact on the current real estate market, visit https://www.teamlally.com/covid19/ 

First we welcome our guest Micheal Wong, a BHSc professor who specializes in neurological sciences (0:00); the difference between the U.S. and Canada (4:47); most and least favorite thing about living in the U.S. (8:00); how Americans view Canadians (13:56); how living away from home shifts your perspective and difference in the education system in the U.S. (17:00); would Mike live somewhere else again for a couple of years? (24:0); a discussion on the recent Atlanta mass shootings and anti-Asian racism (28:40): and we end with a new fun segment called “Spill the Tea” (42:55) Image Creds: http://ability360.org/wp-content/uploads/2018/04/LivAbililty-Edition-12-Advocacy-WP-Header.jpg

   Kim Meacham was diagnosed with a rare form of lymphoma in 2016. With a determined spirit and a supportive wife, Kim went from being given 2 months to live to being in complete remission and feeling healthier than he ever had before. Kim and his wife Ingrid started Health & Success to counsel people to improve their quality of life from preventable or holistically-treatable diseases or conditions. Listen to this podcast to hear about the diet, lifestyle and spiritual changes he made that address all aspects of health necessary for healing. 5:11 Even though I thought I was eating the right way I wasn't. I had an absolute problem with sugar. 5:44 Along with sleep deprivation, I was getting 5-6 hours of sleep a night from the time I was 11 years old. 7:19 I had a hernia surgery in January 2016 and the surgeon detected some lymph node activity. 8:21 I found a lump that came out in the back of my neck. They also started to develop in my armpits and abdominal and groin area. In 12/29/16 I was diagnosed with stage 4 mantle cell lymphoma with 100% proliferation rate. My tumors were doubling in size every week. 10:03 We continued down a holistic path to feed my body so it had the nutrients it needed to survive 4 months of chemotherapy and bone marrow stem cell transplant. 11:50 Bone marrow transplant surgery is one of the most invasive, toxic treatments anyone can go through. 13:21 In the 20 days that I was in the hospital, I walked 92 miles with my IV pole. Other patients started walking for the first time. My energy and true passion to live inspired others. 14:21 I was told I was cancer free but they missed a small cyst in my lower back and it started to grow. I got an appointment with Dr Michael Wong at MD Anderson. 16:48 I told my Dr. not to ever give me an expiration date, so Dr Wong told my family I had less than 2 months to live. There was a clinical trial in phase 2 that was put on hold due to brain toxicity. 18:56 My wife had discovered a dried form of vitamin D mixed with olive oil that was supposed to help reduce tumors on the brain. I had been doing that twice a day for 6 months. When it came time for the trial to begin they couldn't find any lesions on my brain. I was the first person to do this trial after FDA approval. 20:58 I went through a 24 day stay at MD Anderson for the trial. I had a softball size tumor and about 18 other external tumors. We worked hard to support my body through the 400 hours of chemotherapy and never had nausea, diarrhea, mouth sores or a lack of energy. I hid my supplements and herbs from the hospital so they wouldn't take them away. 24:18 It's a travesty the food that hospitals are feeding people that are trying to heal. 25:33 I almost passed away twice during the procedure. I told my Dr. I don't know what dying feels like but I'm not dying. I had a positive attitude and walked 2 miles a day. 30:21 It was my cells, not the chemotherapy, that ultimately took these tumors that were as large as a softball and now they're just ugly scars. 31:00 Take your life in your hands and make your own decisions. Don't let your doctor make your decisions. He's an advisor. It's your life. Make your own decisions. 32:24 Pick a decision and go down that path until something tells you that you need to make a fork in the path. 32:49 SEEDS- Acronym for Sleep, Exercise, Emotion, Diet, and Supplementation at the cellular level. 35:32 I've been a green tea drinker for 40 plus years. 36:20 I do not miss a day of exercise. In 2017 I logged 1800 miles, and 2018 over 2000 miles. That was my internal drive. I do not recommend a hard core workout for someone who had been dormant. I believe in baby steps. 38:07 The emotional part of staying positive and focused on the task at hand is the biggest challenge. Meditation and prayer is a huge part of our life. I believe in energy. Positive energy from people praying for you makes a huge difference. 39:30 We eat 100 % organic, non GMO whole food. We have a substantial garden that I pick from. 40:22 I don't tell anyone not to eat meat, but I personally don't eat meat. If you do eat meat choose organic, pasture raised meat. 42:38 Do not eat dairy products. They are very inflammatory. 45:00 Processed and packaged is still processed and packaged. Read the ingredients. 45:55 Sleep deprivation and sugar were the culprits for my cancer. 47:53 It's so important to have a cohesive family unit or support system for your treatment decisions. The vast majority of people that succumb to cancer succumb from a secondary diagnosis or from the treatments. The statistics just don't prove that these treatments work for the vast majority 58:36 You need a cancer coach that tells you like it is, that gives you a direction that's an option. What worked for me might not work for you, but I know that within a wide range of options there will be something that resonates with you. Because the only thing that works is something that you will follow. 1:00:1:01 I love the Beat Cancer site. You are providing a tremendous service to thousands of people and that's why I decided to get the Cancer Coaching certificate because I have so much respect for what you are doing. Kim Meacham Plano, Texas 214-236-2619 Info@healthandsuccess.com www.HealthandSuccess.org Kihealthandsuccess-Facebook, Instagram,YouTube

From Stark Headquarters, in Irvine, California, in the heart of Orange County, brings you Episode 28 of The C-Life: An Innovative Way to Control Your HVAC, CEO of Genea: Michael Wong. In this episode, Tyler Mounce sits down with Michael Wong and talk about how he and his team created a convenient and innovative way for tenant to control their HVAC from their smart phone. By doing so, they have become a company that has changed the game for tenants and their high HVAC bills. Listen to his awesome story on this episode of the C-Life!